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A panel of EB virus replicon-based vectors was constructed to examine the relative utility of four distinct eukaryotic promoters for high-level gene 
expression in a HTLV-I-transformed human T cell line, HUT102. We found that HTLV-I LTR, which is trans.-activated by the viral tax protein, 
was most suited for EBV vector-based stable gene expression in it. We prepared a HTLV-I LTR-directed antisense c-myc construct with an EBV 
vector. This antisense plasmid suppressed c-myc expression and inhibited growth of HUT102 cells in vitro with unaltered expression of tax. 
Non-specific plasmid toxicity was excluded by showing that the antisense construct had little effect on growth and c-myc expression of HTLV-I- 
negative Jurkat T cells, in which the viral LTR is expected to be less active. Our results indicate that c-myc may play an important role in the 
deregulated growth of HTLV-I-transformed T cells. 
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1. INTRODUCTION 
HTLV-I is etiologically associated with ATL [l-3], 
and can immortalize primary human T cells in vitro 
[4,5]. HTLV-I does not carry a typical one gene in its 
genome, but has a unique 3’ region designated as pX 
besides three common retroviral genes [6,7]. The pX 
region encodes the viral trans-activator, tax protein, 
which can transcriptionally activate its own LTR [8-lo] 
as well as several cellular gene promoters [ 1 l-l 51. Albeit 
many previous experiments have suggested that the tax 
protein contributes to the virus-associated immortaliza- 
tion and malignant transformation of T cells [l l-191, 
the long latency of disease onset implies that the viral 
infection represents a necessary but an insufficient step 
by itself in leukemogenesis. 
To analyze the roles of specific genes, including 
known oncogenes and suppressor genes, in the genesis 
of ATL and HTLV-I-mediated immortalization of 
human T cells, gene transfection strategies in HTLV-I- 
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infected cells may offer powerful approaches. To date, 
however, there has been no systemic investigation about 
gene transfection and expression in such cells. We have 
therefore explored the use of EBV replicon as expres- 
sion vector for achieving high-level sense and antisense 
RNA transcription in a HTLV-I-transformed human T 
cell line, HUT102. We describe a comparative func- 
tional analysis of a selected panel of eukaryotic promot- 
ers in it and utility of HTLV-I LTR for such purposes. 
We have also constructed HTLV-I LTR-directed anti- 
sense c-myc vector to dissect a biological role of c-myc 
in HTLV-I-transformed cells since it has never been 
directly examined whether c-myc is indispensable for the 
deregulated growth of HTLV-I-transformed, tax-ex- 
pressing human T cells. This antisense plasmid has sup- 
pressed c-myc expression and inhibited growth of 
HUT102 cells in vitro. These results indicate that c-myc 
may play an important role in the growth regulation of
HTLV-I-transformed T cells. 
2. MATERIALS AND METHODS 
2.1. Plasmid construction 
The selected promoters and CAT gene were assembled in a multi- 
cloning site of the EBV replicon-based vector ~220.2 [20] as illustrated 
in Fig. 1; pE2/RSVCAT was constructed with RSV LTR derived from 
RSVCATcx/220.2 (provided by M.L. Tykocinski; [20]); pE2/ 
CMVCAT with the CMV immediate arly promoter [21] from CDMI; 
pE2/H@APrCAT with the human B-actin 5’ promoter region from 
pI+!IAPr-1-neo [22]; and pE2/HTLV-ICAT with the HTLV-I LTR 
from pCHL4 (provided by K. Sugamura; [lo]); pE2/0CAT (pro- 
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moter-less CAT) was generated from pEZ/RSVCAT by excising the 
promoter region. 
An antisense human c-myc RNA expression vector was prepared 
as follows (Fig. 1). A 1.4-kb AccII-AvuIII fragment containing exons 
2 and 3 of human c-myc cDNA was excised from pBRmyc (provided 
by T. Naoe). After attaching the Hind111 linker to the blunted AvaIII 
site, the fragment was ligated into the backbone fragment of HindIII- 
BgfII-digested pMTVdhfr to generate pAMYC. A 2.2-kb HindIII- 
BumHI CAT gene fragment in pE2/HTLV-ICAT was exchanged for 
a 2.3-kb HindIII-EarnHI fragment, containing the antisense c-myc 
and SV40 early splice and polyadenylation signals, of pAMYC to 
generate pE2ILAMYC. 
2.2. Cell culture and transfection 
HUT102, a HTLV-I-transformed human CD4’ T cell line [1,23], 
and Jurkat, a HTLV-I-negative human T cell line, were cultured in 
RPM1 1640 with 10% FCS. Five million cells were transfected with 
50 pg of vector DNA by electroporation (Gene Pulser; Bio-Rad, 
Richmond, CA) at 350 V in PBS. The cells were then seeded on 48-well 
culture plates at 1 x lO’/well. Two days later, selection was begun with 
250 &ml of hygromycin B (Calbiochem, La Jolla, CA). 
2.3. CAT assay 
CAT assay was performed as previously described [24]. Briefly, cells 
(5 x 106) were lysed in 100~1 of250 mM Tris-HCl (pH 7.8) and cellular 
extracts (30 ~1) were mixed with 0.1 PCi of [‘Hlacetyl coenzyme A 
(DuPont-NEN, Boston, MA) and chloramphenicol. The mixtures 
were then overlaid with water-immiscible scintillation fluid 
(Econofluor; DuPont-NEN) in glass scintillation vials. After the enzy- 
matic reaction proceeded at 37°C for 1 h, radioactive acetylated chlor- 
amphenicol diffusing into the scintillation fluid was detected by a 
liquid scintillation counter. 
2.4. Southern and Northern blots 
Total DNA was isolated by SDS-proteinase K digestion with exten- 
sive dialysis [24]. EarnHI and EcoRI digested samples (10 pg) were 
separated by electrophoresis on 0.8% agarose, transferred to a nylon 
membrane (Gene Screen plus; DuPont-NEN) and detected using the 
AccII-AvuIII fragment of c-myc cDNA labeled by random-primer 
extension (Amersham, Bucks, UK) with [c+“P]dCTP. Hybridization 
and washing were performed as instructed by DuPont-NEN. 
RNA was prepared using guanidinium thiocyanate-CsCl centrifu- 
gation [24]. Total RNA (15 pg) was electrophoresed on a 1.2% aga- 
rose-formaldehyde gel and transferred to a nylon membrane. To de- 
tect sense or antisense c-myc transcripts, a 0.36-kb Clal-MspI frag- 
ment of c-myc cDNA exon 3 was subcloned into the plasmid 
pBluescript SK(+) (Stratagene, La Jolla, CA), then [a-‘2P]UTP-la- 
beled sense or antisense RNA probes were prepared from the linear- 
ized plasmids using T7fT3 RNA polymerases. Membranes were hy- 
bridized with RNA probes and washed at 70°C twice in 2 x SSC, 1% 
SDS for 20 min each and twice in 0.1 x SSC, 1% SDS for 20 min each. 
2.5. Western blot 
Cells were lysed in SDS sample buffer. Samples were size-fraction- 
ated by SDS-PAGE (9%) and electroblotted onto PVDF membranes 
(Immobilon; Millipore, Bedford, MA). The protein blots were blocked 
in PBS with 5% non-fat dry milk. The membranes were reacted with 
anti-c-myc mAb CT14 (obtained from ATCC) or antip4Otux mAb 
Lt4 (provided by Y. Tanaka; [25]) followed by incubation with perox- 
idase-labeled goat anti-mouse IgG antibodies (Cappel, West Chester, 
PA). The probed proteins were visualized using the ECL system 
(Amersham). 
2.6. Cell growth studies 
Logarithmically growing cells were pelleted, washed with medium 
and resuspended at a concentration of 1 x 105/ml in fresh medium 
containing 10 or 2% FCS. The cell suspension was portioned at 
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4 x lO?well into 48-well plates and cultured. At daily intervals thereaf- 
ter, the viable cell number in each well was determined by Trypan blue 
exclusion in a hemocytometer. 
3. RESULTS 
3.1. HTLV-I LTR provides high-level promoter activity 
in stably transfected HUT102 cells 
To develop high-efficiency transfection and an ex- 
pression system in HTLV-I-infected T cells, we compar- 
atively monitored the activity of selected eukaryotic 
promoters, the RSV LTR, the CMV immediate early 
promoter, the human/3-actin promoter and the HTLV-I 
LTR with an EBV replicon-based vector in a HTLV-I- 
transformed human T cell line, HUT102 by stable CAT 
expression [20]. These constructs were transfected into 
HUT102 cells by electroporation. After 3 weeks in hy- 
gromycin B selection, the transfection efficiency was 
determined (Table I). The vectors carrying the CMV 
promoter or the HTLV-I LTR revealed high transfec- 
tion efficiency, whereas others were similar to that of 
the promoterless construct. 
CAT assays were performed by transfectants with 
various promoter-CAT/220.2 constructs (Fig. 2). 
Among 4 promoters, the HTLV-I LTR yielded the 
B H 
I SW0 poly A I IPrI 
Fig. 1. Structure of the EBV rep&on-based expression plasmid. Upper 
boxes represent an expression cassette consisting of various promoters 
(Pr) as detailed in the text, CAT or antisense c-myc gene (stippled box) 
and SV40 early splice and polyadenylatin signals (SV40 poly A). The 
expression cassette was inserted into the EBV replicon-based vector 
~220.2 containing the EBV origin of replication (EBV oriP), the EBV 
nuclear antigen 1 (EBNA-I), bacterial hph gene (hph), herpes simplex 
virus thymidine kinase gene promoter and polyadenylation signal 
(HSV TK Pr and HSV poly A), as well as pBR322-derived sequences 
for bacterial propagation (hatched box). E, EcoRI; B, BarnHI; H, 
HindIII. 
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Fig. 2. CAT enzymatic activities in HUT102 cells stably transfected 
with ~220.2 carrying various promoter-CAT constructs, HUT102 cells 
were transfected with 50 pug of each plasmid by electroporation. 
Pooled transfectants corresponding to each plasmid were used for 
CAT assay as described in section 2. 
highest promoter activity. This was loo-fold more ac- 
tive than the RSV LTR, which is reportedly an efficient 
promoter in human cytotoxic T cell clones and therefore 
used in antisense RNA-mediated gene inhibition studies 
[20]. The CMV promoter, one of the most efficient 
eukaryotic promoters, was also 5-fold more active than 
the RSV LTR, but was much less active than HTLV-I 
LTR. The human j?-actin promoter demonstrated low 
acetylation values. The strong promoter activity of the 
HTLV-I LTR was also supported at the transcriptional 
level by Northern analysis in other HUT102 transfec- 
tants harboring an antisense HTLV-I env construct sim- 
ilarly driven by each promoter (data not shown). 
3.2. The HTLV-I LTR-directed antisense c-myc con- 
struct reduces c-myc expression in HUT102 cells 
We used the HTLV-I LTR to express antisense c-myc 
RNA in HUT102 cells. The p220.2-based antisense c- 
myc RNA expression plasmid termed pE2/LAMYC 
Table 1 
Transfection efficiency of the EBV-based vector carrying various pro- 
moter-CAT constructs in HUT102 cells* 
8 of wells containing hygromycin B resistant colonies 
OCAT** RSVCAT WAPrCAT CMVCAT HTLV-1CAT 
Exp.1 12 ND*** 42 94 ND 
2 2 8 10 96 90 
3 4 25 10 ND 100 
* HUT102 cells (5 x 106) were transfected with 50 pug of EBV repli- 
con- based vector ~220.2 containing each promoter-CAT expres- 
sion cassette by electroporation and seeded into 48-well culture 
plates at 1 x lO’/well. After three weeks in hygromycin B selection 
(250 &ml), the number of wells containing antibiotic resistant 
colonies was counted using an inverted microscope. 
** Each promoter-CAT construct was inserted into ~220.2. 
***ND. not determined. 
with the HTLV-I LTR, was constructed as described in 
section 2. We also prepared a control plasmid, pE2/ 
LACD4, which contained antisense CD4 (provided by 
H. Nakauchi) in place of c-myc in pE2/LAMYC. Plas- 
mids pE2/LAMYC and pE2/LACD4 were stably intro- 
duced into HUT102 cells like pE2/HTLV-ICAT. The 
efficiency of transfection was equal for all these plas- 
mids. 
We established three antisense c-myc lines carrying a 
complete and unrearranged antisense c-myc expression 
cassette. Southern blot hybridization of total DNA with 
a human c-myc cDNA probe revealed only endogenous 
c-myc sequences in HACD4, the control bulk pE2/ 
LACD4 cells (Fig. 3a). In LAMP2, LAMP5 and 
LAMC2 antisense c-myc lines, an additional 4.3-kb 
band, the expected size for antisense c-myc construct, 
was detected (Fig. 3a). The copy number of the anti- 
sense c-myc was estimated at l-2 copies per cell. 
To examine the expression of antisense c-myc RNA, 
Northern blotting was performed. Total RNA was hy- 
bridized with strand-specific RNA probes to identify 
sense or antisense transcripts. In addition to back- 
grounds due to ribosomal RNA, all three lines ex- 
pressed 2.4-kb antisense RNA but expression levels 
were more prominent in LAMP5 and LAMC2 than in 
LAMP2 (Fig. 3b). No obvious reduction in the steady- 
state level of 2.4-kb endogenous c-myc mRNA was ob- 
served in antisense lines when compared with control 
HACD4 line (data not shown). 
We then investigated expression levels of c-myc pro- 
tein by Western blotting (Fig. 4a). It was conceivable 
that suppression of c-myc leads to alteration in total 
amount and distribution of cellular proteins. Thus, we 
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Fig. 3. (a) Southern blot of introduced antisense c-myc plasmid in 
HUT102 transfectants. Total DNA prepared from control antisense 
CD4 expression plasmid transfectant (HACD4) and antisense c-myc 
expression plasmid transfectants (LAMP2, LAMP5 and LAMCZ) was 
digested with EcoRI and BumHI and Southern blotted with a “P- 
labeled human c-myc cDNA probe. Upper bands represent an en- 
dogenous c-myc gene, whereas the lower bands of 4.3-kb indicate the 
presence of a complete and unrearranged antisense c-myc RNA ex- 
pression cassette (see Fig. 1). (b) Expression of antisense c-myc tran- 
script3 in HUT102 transfectants. Total RNA prepared from control 
or antisense lines was analyzed by Northern blot hybridization with 
a 32P-labeled RNA probe complementary to antisense c-myc. 
17 
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Fig. 4. Western blot of the c-myc (a) and tax (b) proteins in HUT102 
transfectants. Control HACD4 and antisense c-myc lines LAMPZ, 
LAMPS and LAMCZ were cultured in medium with 10% or 2% FCS 
for 48 h, harvested and lysed in SDS sample buffer. Lysates equivalent 
to 5 x 10’ cells were analyzed with mAb for c-myc or tax. Rat-l and 
human c-myc-transfected Rat-l cells were also included in Western 
blot of c-myc as negative and positive controls. 
adjusted loading dose of lysates for each lane by cell 
number rather than by total protein amount. When 
transfectants were cultured under 10% FCS condition, 
two antisense lines, LAMP5 and LAMC2, showed 
somewhat reduced c-myc protein levels compared to 
HACD4. A notable reduction in the steady-state level 
of c-myc protein was observed in these two lines when 
cultured in medium with 2% FCS (Fig. 4a). LAMP2 and 
the control HACD4 exhibited comparable c-myc pro- 
tein levels under a similar 2% FCS condition. It is not 
clear whether two additional bands (70 kDa and 50 
kDa) detected by anti-c-myc mAb CT14 are antigeni- 
tally related to c-myc. Densitometric analysis showed 
that in LAMP5 and LAMC2, the intensity of c-myc 
bands decreased to 25% and 29% of that in the control 
HACD4 cells under 2% FCS condition whereas 50 kDa 
bands did to 62% and 84%, respectively. Although we 
do not know exact reasons for reduction in the levels of 
these additional bands, we believe that c-myc protein 
amount per cell specifically decreased in LAMP5 and 
LAMC2 antisense lines. Inconsistent loading of samples 
was excluded by reproducibility of results and also by 
unaltered tax protein levels in same samples. The levels 
of antisense RNA seemed to correlate with c-myc sup- 
pression (Figs. 3b and 4a). As described above, no dif- 
ference of tax expression was observed between 
HUT102 transfectants with reduced and non-reduced 
c-myc expression, whether they were cultured in me- 
dium with 10% FCS or with 2% FCS (Fig. 4b). 
3.3. Inhibited cell growth of c-myc-suppressed HUT102 
cells cultured under lowered serum conditions 
The growth characteristics of the transfectants were 
then investigated. In the presence of 10% FCS, the anti- 
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Fig. 5. Cell growth of control HUT102 lines HACD4 or HLCAT 
(pooled pE2/HTLV-ICAT transfectants) and antisense c-myc lines 
LAMPZ, LAMP5 or LAMCZ in the presence of 10% (a) or 2% (b) 
FCS. Logarithmically growing cells in medium with 10% FCS were 
pelleted and resuspended at a concentration of lO’/ml in fresh medium 
containing the indicated concentration of FCS. Cells were daily 
stained with trypan blue and counted in a hemocytometer. Similar 
results were obtained in three separate xperiments. 
sense lines LAMP2, LAMP5 and LAMC2 grew as well 
as the control lines HACD4 and HLCAT (pooled pE21 
HTLV-ICAT transfectants) (Fig. 5a). The c-myc-sup- 
pressed lines, LAMP5 and LAMC2, however, showed 
apparently reduced-growth rates in medium containing 
2% FCS. At day 5, viable cells in c-myc-reduced lines 
remained at about half that of the control lines (Fig. 5b). 
Reduced thymidine incorporation into the HUT102 
cells with suppressed c-myc was also observed during 
the culture with lowered serum condition (data not 
shown). LAMP2 having normal c-myc protein with a 
moderate antisense RNA expression showed slightly re- 
duced growth property (Fig. 5b). 
3.4. HTLV-I LTR-directed antisense c-myc construct 
does not influence growth of HTLV-I-negative Jur- 
kat T cells 
It is known that HTLV-I LTR is strongly trans-acti- 
vated by the viral tax protein. Thus, we monitored the 
effect of the viral LTR-directed antisense c-myc plasmid 
in HTLV-I-negative cells. We introduced pE2/LAMYC 
and control pE2/LACD4 into a HTLV-I-negative 
human T cell line, Jurkat, and obtained a control line 
and two antisense lines carrying a complete and unrear- 
ranged antisense c-myc expression cassette (Fig. 6a). 
These two lines showed a marginal change, if any, in 
c-myc expression and proliferation rate under 2% FCS 
condition when compared with control pE2/LACD4 
line (Fig. 6b and c). These results indicate that HTLV-I 
LTR-directed antisense c-myc plasmid was less active in 
HTLV-I-negative cells and also was not non-specifically 
toxic. 
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Fig. 6. (a) Southern blot of introduced antisense c-myc plasmid in 
Jurkat transfectants. Total DNA (10 pg) prepared from control line 
JACD4 (pEULACD4 transfectant) or antisense c-myc lines JAM1 and 
JAM2 (pE2ILAMYC transfectants) was Southern blotted with a 
human c-myc probe. (b) Western blot of c-myc protein in Jurkat 
antisense c-myc lines cultured in 2% FCS. Lysates equivalent to 1 x lo6 
cells were analyzed with mAb for c-myc. (c) Cell growth of Jurkat 
antisense c-myc lines in the presence of 2% FCS. 
4. DISCUSSION 
4.1. c-myc may play an essential role in deregulated 
growth of HTLV-I-transformed T cells 
c-myc, one of proto-oncogenes, encodes a nuclear 
oncoprotein which contains both DNA binding and 
protein dimerization motifs and may also act as a tran- 
scription factor [26]. It has been observed that c-myc is 
important for cell growth, cell transformation, cell dif- 
ferentiation and also programmed cell death [27-331. 
Several experiments using an antisense strategy have 
provided direct evidence confirming such a role for c- 
myc [28-31,331. We decreased the c-myc expression of 
a HTLV-I-transformed human T cell line HUT102 with 
a HTLV-I LTR-directed antisense construct. The sup- 
pressive effect of antisense c-myc transcripts became 
more apparent when the cells were cultured at a lowered 
serum concentration (Fig. 4a). One explanation for this 
may be the fact that in HUT102 cells, reduced FCS 
concentration appeared to induce repressed expression 
of c-myc (Fig. 4a). On the other hand, expression of tax, 
which is transcribed from the viral LTR, was not af- 
fected by the reduced serum concentration (Fig. 4b), 
suggesting that LTR-directed antisense activity was es- 
sentially unchanged under similar conditions. 
Previous reports showed that decreased c-myc expres- 
sion by antisense RNA leads to increased serum de- 
pendency for growth of murine erythroleukemia cells 
[31] and ras-transformed NIH3T3 cells in vitro [33]. In 
our study, the c-myc-suppressed HUT102 lines 
(LAMP5 and LAMC2) displayed increased growth fac- 
tor requirements for cell growth, while their growth in 
10% FCS medium did not deteriorate too much (Fig. 5). 
Although growth suppression of antisense cells seemed 
to correlate with the c-myc protein levels, LAMP2 hav- 
ing comparable c-myc protein with a moderate anti- 
sense RNA expression showed slightly reduced growth 
property (Figs. 3b, 4a and 5b). It may be possible that 
antisense RNA partially intluenced growth of this line, 
for reasons not clear at present. Non-specific toxicity of 
the plasmid was excluded by showing that the antisense 
construct had little effect on growth of HTLV-I-nega- 
tive Jurkat T cells (Fig. 6), in which the viral LTR is 
expected to be less active. 
The immortalizing and oncogenic potential of tax has 
been suggested by several investigators [16-191. Similar 
to other viral nuclear proteins such as SV40 T and 
adenovirus Ela, cotransfection of tax (in place of c- 
myc) into rat embryo fibroblasts with the ras oncogene 
induced neoplastic transformation [18,27,34]. This find- 
ing suggests functional compatibility between c-myc 
and tax. Recently, M.P. Duyao et al. reported that tax 
activates murine c-myc promoter via NFKB sites [35]. 
They also described that tax can activate the human 
c-myc promoter [35]. On the other hand, stably intro- 
duced tax had no effect on endogenous c-myc expres- 
sion in Jurkat T cells [36]. In our analysis, c-myc-sup- 
pressed and growth-inhibited HUT102 transfectants 
showed unchanged tax protein levels (Figs. 4 and 5). 
While this constitutive expression of the tax protein 
ensured antisense transcription from the viral LTR, 
these results proved the inability of tax to functionally 
replace c-myc in growing HUT102 cells. Expression of 
c-myc may therefore stay critical for growth of these 
cells. Further investigation about the role of c-myc in 
terms of tax-mediated immortalization and tumor de- 
velopment is ongoing in our laboratory. 
4.2. The utility of the HTLV-I LTR-directed stable ex- 
pression vector with the EBV replicon in HTLV-I- 
infected cells 
The development of stable transfection strategies for 
directing high-level gene expression in HTLV-I-infected 
cells may offer a useful clue for analyzing the cellular 
physiology of virus-infected cells as well as for designing 
an effective gene therapy to eliminate HTLV-I-infected 
cells. The HTLV-I LTR is appropriate since it gave high 
acetylation values in stable CAT experiments (Fig. 2) 
and also showed sufficient level of antisense xpression 
in HUT102 cells (Fig. 3b). Since the promoter activity 
of HTLV-I LTR increases to 50- to loo-fold in the 
presence of tax [8-lo], the LTR may be suitable for 
achieving high levels of selective antiviral or antiprolif- 
erative gene expression in tax-expressing cells. In our 
investigation, HTLV-I LTR-directed antisense c-myc 
construct seemed to be less active in virus-negative Jur- 
kat cells than virus-infected HUT102 cells, indicating a 
possible therapeutic application of our antisense strat- 
egy. Recently, similar in vitro approaches for the human 
immunodeficiency virus have been attempted using the 
HIV LTR-directed expression systems [37,38]. To- 
19 
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gether, these results indicate the usefulness of the 
HTLV-I LTR-directed vector for attaining sense and 
antisense xpression in HTLV-I-infected cells. 
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